Do GLP-1 Medications Cause Muscle Loss? What the Evidence Shows

GLP-1 medications can be accompanied by a reduction in lean body mass as people lose weight, but that does not mean everyone taking these medications is losing a dangerous amount of skeletal muscle. It also does not mean GLP-1 treatment automatically causes sarcopenia.

That distinction matters because headlines about “muscle loss” often combine several different measurements. Clinical studies frequently report lean mass, which includes more than skeletal muscle. Meanwhile, muscle health depends not only on how much muscle tissue a person has, but also on strength, muscle quality, and physical function.

Current evidence suggests that medications such as semaglutide and tirzepatide generally produce substantially greater losses of fat than lean tissue. Some lean-mass loss is common, as it is with other forms of significant weight loss. What remains less certain is how much of that change represents actual skeletal-muscle loss, whether GLP-1 medications have a muscle-wasting effect beyond weight loss itself, and which patients are most vulnerable to clinically important declines.

Why weight loss can include lean tissue

The body does not lose only stored fat when body weight decreases. During a sustained calorie deficit, reductions can occur in fat mass as well as components of fat-free or lean mass.

That happens with diet-induced weight loss, bariatric surgery, and medication-assisted weight loss. The amount varies according to factors such as the magnitude and rate of weight loss, age, starting body composition, dietary intake, physical activity, and whether resistance exercise is included.

A 2026 meta-analysis of 20 randomized controlled trials involving 15,782 participants found that lean mass accounted for about 25% to 39% of total weight lost with the incretin-based treatments studied. Importantly, the proportional lean-mass loss was broadly comparable with intensive lifestyle-based weight loss in that analysis. Lifestyle intervention combined with resistance training had a more favorable lean-mass profile than lifestyle intervention alone.

That finding makes the phrase “GLP-1 medications cause muscle wasting” too simplistic. Some loss of non-fat tissue accompanies substantial weight reduction regardless of how the weight is lost. Researchers are still working out whether certain GLP-1-based treatments have additional direct effects on skeletal muscle beyond the effects of weight loss, reduced food intake, and changes in activity.

Lean mass and skeletal muscle are not interchangeable

This is one of the most important points for interpreting GLP-1 research.

Lean body mass generally refers to body mass that is not fat. Depending on the measurement method, it includes skeletal muscle but also organs, connective tissues, body water, glycogen-associated water, and other non-fat components.

A DXA scan, for example, estimates lean soft tissue. It does not directly measure individual skeletal muscles throughout the body. Bioelectrical impedance analysis, or BIA, estimates fat-free mass through another indirect method.

A 2026 review of GLP-1-based obesity treatment specifically cautioned that DXA-derived lean mass and BIA-derived fat-free mass should not be treated as equivalent to skeletal-muscle mass. The review also noted that a reduction in lean tissue does not necessarily indicate worsening strength or physical performance.

This means a statement such as “30% of weight loss was lean mass” should not automatically be translated into “30% of the weight lost was muscle.”

Changes in hydration can also affect measurements of lean tissue. Significant weight loss alters glycogen stores, water balance, and tissue composition, adding another reason to interpret body-composition numbers in context.

What semaglutide studies show about body composition

An exploratory body-composition analysis from the STEP 1 trial offers one of the best-known examples.

The analysis included 140 adults with overweight or obesity who underwent DXA measurements. After 68 weeks, participants receiving semaglutide 2.4 mg had lost about 15% of their body weight on average.

Total fat mass decreased by 19.3%, while total lean body mass decreased by 9.7%. Because fat declined more rapidly than lean mass, lean mass actually represented a larger percentage of total body weight after treatment than it did at baseline. The ratio of lean mass to fat mass also improved.

These findings demonstrate two things at the same time:

• Absolute lean mass decreased.
• Overall body composition shifted toward a greater proportion of lean tissue relative to fat.

Both statements are true.

What the study does not establish is that every kilogram categorized as lost lean mass was skeletal muscle or that participants experienced an equivalent decline in muscle strength.

That limitation is important because the STEP 1 body-composition substudy was primarily designed to measure changes in body compartments, not to diagnose sarcopenia.

What tirzepatide studies show

A DXA substudy of the SURMOUNT-1 trial provides similar information for tirzepatide, a medication that activates both GIP and GLP-1 receptors.

Among 160 participants in the substudy, body weight decreased by 21.3% over 72 weeks in the pooled tirzepatide groups. Fat mass fell by 33.9%, while lean mass decreased by 10.9%.

Approximately 75% of the weight lost was fat mass and 25% was lean mass. The researchers reported a similar approximate proportion of fat and lean tissue loss in the placebo group, although total weight loss was much smaller with placebo.

Again, the finding confirms that lean tissue can decline during substantial medication-assisted weight loss. But it also shows that fat accounted for most of the weight reduction.

What broader research says

Individual trials can give very different impressions depending on the medication, population, measurement method, and amount of weight lost. Meta-analyses help place those studies in context, although they have limitations of their own.

A 2026 meta-analysis comparing incretin therapies with lifestyle interventions found that the proportion of total weight loss attributed to lean mass was approximately:

Weight-loss approach	Approximate proportion of weight loss reported as lean mass
Semaglutide	35.2%
Tirzepatide	25.4%
Liraglutide	26.8%
Lifestyle intervention	26.2%
Lifestyle plus resistance training	17.5%

These figures came from pooled randomized-trial data and should not be interpreted as predictions for an individual person. The studies differed in treatment duration, participants, interventions, and body-composition methods, and the meta-analysis reported moderate heterogeneity.

Another 2026 systematic review and meta-analysis focused specifically on GLP-1 receptor agonists used at obesity-treatment doses. Across seven randomized studies involving 821 participants, absolute lean mass decreased, while lean mass as a proportion of total body weight increased because fat mass declined more substantially.

At the same time, a separate 2026 meta-analysis emphasized how much uncertainty remains. Only a small number of comparative studies could be included in its primary analyses of muscle quantity, and results were highly heterogeneous and imprecise. Its authors concluded that reductions in lean mass should not automatically be interpreted as sarcopenia, while also cautioning that clinically meaningful muscle loss cannot yet be ruled out in susceptible patients.

Taken together, the evidence supports concern about preserving muscle during major weight loss, but it does not support assuming that GLP-1 treatment inevitably produces pathological muscle wasting.

Is lean-mass loss the same as sarcopenia?

No.

Sarcopenia is a clinical muscle disorder, not simply a lower number on a body-composition scan.

The European Working Group on Sarcopenia in Older People emphasizes low muscle strength as a key characteristic of sarcopenia. Reduced muscle quantity or quality helps confirm the diagnosis, while poor physical performance indicates greater severity.

That is very different from seeing a decrease in total lean mass after weight loss.

Someone could lose some lean tissue while maintaining good strength and physical function. Conversely, another person could have relatively substantial muscle mass but poor muscle quality or declining strength.

Research examining GLP-1 medications and functional outcomes is still developing. For example, a prospective 2026 study of adults with obesity treated with semaglutide found that lean mass initially declined but later stabilized, while handgrip strength improved over 12 months. The study was not a randomized placebo-controlled trial, so it cannot settle the question, but it illustrates why muscle quantity and muscle function should not be treated as identical outcomes.

Why some people may be more vulnerable

Even if average trial results are reassuring in some respects, averages can hide individual risk.

People beginning treatment with relatively low muscle reserves may have less capacity to tolerate additional losses. The concern is particularly relevant when weight loss occurs alongside poor protein intake, prolonged inactivity, illness, or age-related declines in muscle.

Recent clinical reviews identify several groups that may warrant more attention, including people who are:

• older or frail;
• already living with low muscle mass or low strength;
• physically inactive;
• eating very little because of appetite suppression or gastrointestinal symptoms;
• experiencing particularly rapid weight loss;
• living with conditions that already increase the likelihood of muscle loss.

Evidence specific to many of these higher-risk GLP-1 populations remains limited, so recommendations are often informed partly by the broader literature on weight loss, resistance exercise, nutrition, and sarcopenia.

That uncertainty is one reason the most useful question is often not simply “Did lean mass go down?” but rather “What is happening to muscle mass, strength, function, nutrition, and overall health together?”

Does the medication itself directly break down muscle?

This remains unsettled.

One possibility is that much of the lean-tissue change seen with GLP-1 therapy is an expected consequence of substantial weight loss. When a person becomes lighter, the body does not require exactly the same amount of metabolically active and load-bearing tissue that it previously carried.

Reduced calorie intake can also contribute. GLP-1-based medications frequently reduce appetite substantially, and some people may find it difficult to consume enough protein or overall nutrition, particularly if nausea, early fullness, or food aversions are present.

The 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society therefore recommends paying attention to nutrition, physical activity, strength training, muscle function, and body composition rather than viewing medication as a stand-alone intervention.

At present, researchers have not established that the commonly used GLP-1-based obesity medications produce a universal, direct muscle-toxic effect comparable to a disease process that actively destroys muscle tissue.

The more defensible interpretation is that substantial weight loss can include lean-tissue loss, and the clinical importance of that loss depends on what tissue is actually being lost and what happens to strength and function.

Why muscle preservation still matters

Avoiding exaggerated claims about muscle loss does not mean dismissing the issue.

Skeletal muscle supports movement, physical independence, glucose disposal, exercise capacity, and metabolic health. Preserving useful muscle tissue is especially important when people are intentionally losing a large amount of body weight.

The goal is therefore not simply to make the scale fall as quickly as possible. Increasingly, obesity specialists are emphasizing the quality of weight loss: reducing excess fat while preserving as much useful lean tissue, strength, function, and nutritional adequacy as reasonably possible.

Resistance exercise appears particularly important. In the 2026 meta-analysis comparing incretin treatment and lifestyle interventions, lifestyle programs that incorporated resistance training showed a smaller proportion of weight loss coming from lean mass than lifestyle interventions without that emphasis.

Protein and overall nutritional adequacy matter as well, although protein alone should not be viewed as a substitute for using the muscles. The 2025 multisociety advisory emphasizes combining appropriate nutrition with structured resistance or strength training during GLP-1-assisted weight loss.

For practical strategies, see our ways to preserve muscle while taking GLP-1 medications.

How should muscle health be monitored?

A bathroom scale tells you whether body weight is changing, but it cannot tell you what tissue is responsible.

DXA and BIA can provide additional information about body composition, although both have limitations. More importantly, clinicians may also consider what is happening to strength and physical function, especially in people who have greater baseline risk.

Depending on the person, useful information might include changes in:

• ability to perform usual resistance exercises;
• grip strength or other standardized strength measures;
• walking, stair climbing, or chair-rise performance;
• dietary intake and appetite;
• rate of weight loss;
• symptoms such as unusual or progressive weakness;
• body composition when measurement is clinically appropriate.

Routine advanced imaging is not necessary for everyone taking a GLP-1 medication. Monitoring should be individualized according to age, health status, treatment goals, nutrition, physical activity, and other risk factors.

Someone experiencing persistent weakness, substantial difficulty eating enough, declining physical function, or other concerning changes should discuss them with the clinician managing treatment. Prescription medication should not be stopped or adjusted solely because of a body-composition concern without discussing the situation with the prescriber.

The bottom line on GLP-1s and muscle loss

GLP-1-based medications can produce weight loss that includes a measurable decline in lean body mass. That is supported by clinical trials.

But lean-mass loss is not synonymous with skeletal-muscle loss, and skeletal-muscle loss is not automatically sarcopenia.

Studies of semaglutide and tirzepatide generally show that considerably more fat than lean tissue is lost. Current randomized evidence also suggests that the proportion of lean mass lost during incretin-assisted weight reduction can resemble what occurs during substantial lifestyle-induced weight loss.

The remaining concern is not imaginary. Some people—particularly those with lower muscle reserves, older age, poor dietary intake, inactivity, or other risk factors—may be more vulnerable to clinically meaningful muscle loss. Research still needs better measurements of actual skeletal-muscle quantity, muscle quality, strength, and physical function to define that risk more precisely.

For now, the most useful goal is not simply maximum weight loss. It is better-quality weight loss: reducing excess fat while protecting nutrition, strength, muscle function, and long-term physical health.

References

1. Eisa N, Barood O. “Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes, Obesity and Metabolism, 2026.
2. Look M, Dunn JP, Kushner RF, et al. “Body Composition Changes During Weight Reduction With Tirzepatide in the SURMOUNT-1 Study of Adults With Obesity or Overweight.” Diabetes, Obesity and Metabolism, 2025.
3. Wilding JPH, Batterham RL, Calanna S, et al. “Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study.” Journal of the Endocrine Society, 2021.
4. Menezes MLL, Chiappa MEG, Kloss RF, et al. “Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework.” Diabetes, Obesity and Metabolism, 2026.
5. Mozaffarian D, Agarwal M, Aggarwal M, et al. “Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.” Obesity Pillars, 2025.
6. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. “Sarcopenia: Revised European Consensus on Definition and Diagnosis.” Age and Ageing, 2019.